newsletter masthead
June 14, 2019
Dr. Stan Gerson
Stan Gerson, MD
Director, Case Comprehensive Cancer Center

Cancer Mortality Declines Nationally, Findings Depict Need for Continued Efforts in our Catchment Area: National and State Data Available for Download!

Last month the NCI released their   Annual Report to the Nation on the Status of Cancer that reported "for all cancer sites combined, cancer death rates continued to decline in men, women, and children in the United States from 1999 to 2016." While these statistics are encouraging and confirm we have made strides in cancer research over the past 17 years, it is important to understand the importance of our own catchment-related work ahead of us right here in Ohio.
The Ohio Department of Health just released the first Ohio-specific report on Cancer Survival in Ohio that provides a comprehensive examination of five-year relative cancer survival using data from the Ohio Cancer Incidence Surveillance System. A few key findings:
  • Ohio's five-year relative survival for all cancer sites/types combined was statistically significantly lower than that of the United States
  • Females had higher five-year survival than males; blacks typically had lower five-year survival than whites
  • In Ohio, cancer survival was generally lower in the poorest counties than the most affluent counties, lower in rural counties than urban counties and lower in Appalachian counties than non-Appalachian counties
  • Cancer patients in Ohio with private insurance at diagnosis had better survival outcomes than those who were uninsured or had other types of health insurance
Both studies provide an overview, with less comprehensive disease-specific or sufficient demographic data, but these are starting points.

These findings emphasize the importance of addressing issues locally. The Case CCC has an open RFA to support collaborative, multi-investigator pilot projects in catchment-related cancer and risks prevalent in underserved populations. In addition, our Center is making targeted efforts expand our research efforts to include rural counties surrounding our 15-county catchment area.
I encourage you to consider how you can impact research and cancer prevention efforts in our own Ohio communities. Please consider a response to this RFA!
Trainees: Participate in Review of VeloSano Catalyst Fellowship Applications!
The Office of Cancer Training, Education and Research (OCTER) is looking for cancer trainees to participate in the review of the VeloSano Catalyst Fellowship applications. Participants will review applications for the award and participate in the selection committee tasked with making the awards. This is a great opportunity to gain experience in the grant review process and influence training supported by the Case Comprehensive Cancer Center.

Those interested in participating in the review process, please contact Damian Junk at
Registration Opening Soon: Artificial Intelligence in Oncology Symposium
The inaugural Artificial Intelligence in Oncology Symposium: Advancements and Policy will bring together experts in AI and machine learning as well as clinical, industry and federal agency experts in pathology, radiology, oncology and immuno-oncology to speak on research developments, regulatory policy, reimbursement and ethics surrounding AI.

The symposium will feature a number of focused panel discussions and international scientists providing unique perspectives on how analytics can impact the major areas of radiology, pathology and -omics in the contexts of precision medicine approaches for characterizing tumors and predicting therapeutic response.

Beyond the science, attendees will be able to network, explore potential new partnerships and visit exhibitors throughout the day.

Registration for the Artificial Intelligence in Oncology Symposium is opening soon.  Sign up to receive updates>
You're Invited: Celebrate the Establishment of the Helen Moss Foundation-Schoff Family Professorship in Integrative Oncology
June 27, 4:30pm | WRB Auditorium

Please join us on Thursday, June 27 at 4:30pm for a CWRU SOM logo - png program and reception celebrating the establishment of the Helen Moss Foundation-Schoff Family Professorship in Integrative Oncology and the appointment of Richard T. Lee, MD as the inaugural Helen Moss Foundation-Schoff Family Professor of Integrative Oncology.

The event will take place in the auditorium on the first floor of the Wolstein Research Building with complimentary valet parking provided on Circle Drive. Please RSVP by Thursday, June 20, 2019 to or 216.368.3109.
Cheer, Volunteer, Donate or Ride with Team Case CCC
July 19-21, 2019 | Cleveland, OH

We are a little more than one month away from VeloSano Bike to Cure weekend! To-date, Team Case CCC has 61 members  who are committed to cancer research, prevention, treatment and cures and have  raised $23,505  and counting. We've grown by 3 members and raised $2,480 in the past week!

While we are still welcoming riders to our team, you can also get involved by volunteering for our cheer station or donating to any rider or the team as a whole to show your support!
Request for Proposals for the Case Specialized Program of Research Excellence in Gastrointestinal Malignancies
Deadline: July 8, 2019

The Case Comprehensive Cancer Center's   Specialized Program of Research Excellence in Gastrointestinal Malignancies  (GI SPORE) is pleased to announce a new funding opportunity. All faculty members are invited to submit project proposals to compete for R01 level funding for up to three (3) years by selection for incorporation as a full project in the current Case GI SPORE program, with potential for renewal for an additional five (5) years of funding contingent on the future competitive renewal of the GI SPORE program.

All proposals must be directed toward translational research of a GI malignancy with at least one specific aim that involves direct study of patients or of consented human tissues as defined in the  SPORE RFA . View proposal guidelines and application instructions>
Open Funding Opportunities at the Case Comprehensive Cancer Center

The Case Comprehensive Cancer Center is currently Case CCC logo accepting applications for the following additional funding opportunities. Click each opportunity for award descriptions, funding criteria and application instructions.
Community & Collaboration Translational Research Project Pilot Funding Opportunity
Deadline: June 30, 2019

The Community and Collaboration (C&C) component of the Clinical and Translational Science Collaborative (CTSC) is pleased to announce a new  funding opportunity CTSC logo  intended to support, promote and highlight multi-disciplinary collaboratives by providing pilot funding for a Translational Research Project  (TRP) that addresses a particular health issue or problem facing the local community. Applicants must consist of teams that include investigators from more than one discipline and at least one engaged community  stakeholder .

According to National Center for Advancing Translational Science (NCATS) who funds the CTSC, translation is the "process of turning observations in the laboratory, clinic, and community into interventions that improve the health of individuals and the public". Therefore, the CTSC C&C component will focus on awarding TRP projects that can clearly articulate how the project "traverses a particular step of the translation process for a particular target or disease".

Awards for the translational research pilot projects will be granted by the CTSC C&C component.  The C&C will fund two, $30,000 awards and must be expended before April 30, 2020. View full award information, eligibility criteria and application instructions>

2019 Susan G. Komen Career Catalyst Research Grants
LOI Deadline: July 10, 2019

The Susan G. Komen Foundation has released a call for susan g komen logo research proposals focused on redefining metastatic breast cancer through liquid biopsyEarly career breast cancer researchers anywhere in the world are invited to apply for their Career Catalyst Research Grants.

These Komen Training and Career Development awards seek to bridge the funding gap faced by faculty as they start their careers in breast cancer research. Grants funded by Komen provide the preparation necessary to compete for independent funding as an established and successful breast cancer researcher.

The goal of this year's  focus area is to support outstanding research seeking to use liquid biopsy techniques to improve treatment, detection, and understanding of metastatic breast cancer which will lead to a reduction in breast cancer deaths by 2026.

Komen requests Letters of Intent for research projects that address one of the following focus areas:
  • Refining treatment of metastatic breast cancer
  • Early detection of metastatic breast cancer
View the full RFA and application instructions>
Quality of Care Evaluations in Advanced Ovarian Cancer Research Opportunity
LOI Deadline: July 22, 2019

NCCN logo National Comprehensive Cancer Network® (NCCN) and AstraZeneca Pharmaceuticals (AstraZeneca) are collaborating to offer a new funding opportunity for improving patient care and outcomes in Stage III, Stage IV and recurrent epithelial ovarian cancer (EOC).

he intent of this RFP is to encourage investigators at NCCN Member Institutions to submit letters of intent (LOIs) describing concepts for developing, implementing, and evaluating initiatives to improve patient outcomes in Stages III/IV and recurrent EOC. Studies aimed at enhancing the quality of multiple aspects of patient interaction and management throughout the clinical care continuum will be eligible. Special consideration will be given to "outside the box" innovative projects, with a special focus on optimizing testing and effectiveness of new healthcare-related paradigms. Log in to the NCCN Oncology Research Program site to view grant opportunities>

NCCN views this collaboration with AstraZeneca as clear recognition of the advantages offered to NCCN Member Institutions through the NCCN Oncology Research Program.
Oncology Times - June 5, 2019
Deputy Director for Cleveland Clinic Brian Bolwell, MD explains why it's important for leaders to form relationships in a professional setting in his latest contribution to Oncology Times.

Deep Learning Predicts Women's Future Risk of Breast Cancer
Health IT Analytics - June 12, 2019
"If the network can tell which patients have cancer and which do not, this technology can serve as triage for the pathologist, freeing their time to concentrate on the cancer patients," said Anant Madabushi, PhD. Dr. Madabushi directs the Center for Computational Imaging and Personalized Diagnostics at CWRU and is a member of the Case CCC's Cancer Imaging Program.
NIH BULLETIN - Notices and Funding Opportunities
Notice of Clarification to RFA-CA-19-032, "Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)"

Funding Opportunities
Deadline: October 9, 2019 by 5pm
Mon, June 17
Genomic Medicine Institute Seminar
Harpreet Kaur, PhD Kallianpur Lab 
"Plausible Role of the HFE (hemochromatosis) Gene in HIV-Associated  Neurocognitive Disorder"
Vijay Nagampali, PhD
Blackenberg Lab 
A Machine learning based approach for predicting aberrant activity of PI3K pathway in cancer"
12p NE1-205
Tues, June 18
Cancer Drug Discovery and Resistance 
3p WRB 1-422D
Weds, June 19
Biomedical Innovation & Entrepreneur Club:
Discussion and Networking Happy Hour
4-6p Sears think[box]
Thurs, June 20
Developmental Therapeutics Journal Club
9a N E 6-218

Molecular Biology and Microbiology Seminar
1p SOM W203
Fri, June 21
Taussig Cancer Institute Grand Rounds - CCF ONLY
James Kochenderfer, MD
National Cancer Institute
"Chimeric Antigen Receptor T-cell Therapy for Lymphoma and Multiple Myeloma"
8a CA5-120
Mon, June 24
Dept. of Pathology Defense
Jin Young (Leo) Kim
Rich Lab
"Metabolic Control of Stem-Like Epigenome in Glioblastoma Stem Cells"
1p WRB Auditorium
Weds, June 26
ASCO Review
7:30a-4p Intercontinental
Thurs, June 27
Developmental Therapeutics Journal Club
9a NE6-218

Molecular Biology and Microbiology Virology Journal Club
1p SOM W203
Fri, June 28
Taussig Cancer Institute Grand Rounds
Eren Berber, MD
"An Update on Minimally Invasive Treatment of Malignant Liver Tumors"
8a CA5-120

Deadline: Open

Deadline: Open

Deadline: Open
Case Comprehensive Cancer Center